SIGLEC1 and cancer: in 2023 in Advanced Materials, discussed an acid-ionizable iron nanoadjuvant developed to enhance antigen cross-presentation in CD169+ APCs with robust STING cascade activation for personalized cancer vaccination immunotherapy (28).